The Top 5 Biosimilar Articles for the Week of November 29

Here are the top 5 biosimilar articles for the week of November 29, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of November 29, 2021.

Number 5: Regulators are at work clarifying biosimilar guidance and on Capitol Hill, a battle is raging over reforms that could help or hurt biosimilar advancement.

Number 4: Authors of a new study estimated significant savings from biosimilars in Ontario based on deep price discounts and mandatory switching programs.

Number 3: A study of trastuzumab biosimilars and the reference product (Herceptin) under control and stress conditions elucidated the value of machine learning.

Number 2: Specialty tiers for biosimilars and reforms that address the proliferation of poor-quality patents would help lower costs and improve access, biosimilar industry veterans said.

Number 1: An expert on biotherapeutics recommended more science be applied to World Health Organization (WHO) biosimilar guideline revisions.

To read all of these articles and more, visit centerforbiosimilars.com.